在欧洲严重喘患者中,COVID-19疫苗接种的接受性,安全性和副作用
Apostolos Bossios1,2,3, Alison M Bacon4, Katrien Eger5
1Karolinska Severe Asthma Center, Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Huddinge, Sweden.
ERJ open research
|November 29, 2023
概括
在欧洲各地的严重喘患者中,接种疫苗的比例很高. 大多数人经历了轻微的副作用,而COVID-19疫苗接种并没有对喘控制产生负面影响,这表明它是安全和耐受的.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 公共卫生 公共卫生
背景情况:
- 疫苗接种犹威胁到人口对SARS-CoV-2的免疫力.
- 慢性免疫抑制患者,特别是喘患者接受疫苗的情况尚不清楚.
- 在严重喘患者中调查COVID-19疫苗接种经验至关重要.
研究的目的:
- 评估COVID-19疫苗接种接受度和严重喘患者的体验.
- 探索疫苗接种信仰,副作用和喘控制之间的关系.
- 评估严重喘患者的安全感知和疫苗推率.
主要方法:
- 一项关于疫苗接种信仰 (VAX尺度),副作用和喘控制的调查,分发给12个欧洲国家的严重喘患者.
- 数据收集发生在2021年5月至6月期间.
- 660名参与者填写了问卷,回复率为87.4%.
主要成果:
- 在严重喘患者中观察到高接种率 (88%接种疫苗或打算接种疫苗).
- 负面的疫苗接种信念与犹或拒绝相关.
- 大多数患者报告轻度或没有副作用,对喘控制的影响最小;98%的人会建议接种疫苗.
结论:
- 在欧洲,严重喘患者中,COVID-19疫苗接种率很高.
- 接种疫苗的信念显著影响了接种疫苗的接受度和副作用报告.
- 在这个人群中,COVID-19疫苗接种是安全的,耐受性很好,对喘控制的影响很小.
相关概念视频
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: β2-Adrenoceptor Agonists
272
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
272
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
270
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
270


